Extracellular-Regulated Protein Kinase 5-Mediated Control of p21 Expression Promotes Macrophage Proliferation Associated with Tumor Growth and Metastasis

Emanuele Giurisato1,2, Silvia Lonardi3, Brian Telfer4, Sarah Lussoso1, Blanca Risa-Ebrí2, Jingwei Zhang2, Ilaria Russo5,6, Jinhua Wang7,8, Annalisa Santucci1, Katherine G. Finegan4, Nathanael S. Gray7,8, William Vermi3,9, and Cathy Tournier2

ABSTRACT

The presence of immunosuppressive macrophages that become activated in the tumor microenvironment constitutes a major factor responsible for tumor growth and malignancy. In line with this knowledge, we report here that macrophage proliferation is a significant feature of advanced stages of cancer. Moreover, we have found that a high proportion of proliferating macrophages in human tumors express ERK5. ERK5 was required for supporting the proliferation of macrophages in tumor grafts in mice. Furthermore, myeloid ERK5 deficiency negatively impacted the proliferation of both resident and infiltrated macrophages in metastatic lung nodules. ERK5 maintained the capacity of macrophages to proliferate by suppressing p21 expression to halt their differentiation program. Collectively, these data provide insight into the mechanism underpinning macrophage proliferation to support malignant tumor development, thereby strengthening the value of ERK5-targeted therapies to restore antitumor immunity through the blockade of protumorigenic macrophage activation.

Significance: These findings offer a new rationale for anti-ERK5 therapy to improve cancer patient outcomes by blocking the proliferative activity of tumor macrophages.

Introduction

Tumor-associated macrophages (TAM) are the most abundant cell types across the majority of cancers analyzed (1). Their exquisite ability to shape their phenotype in response to external stimuli allows them to exhibit multifaceted functions in the tumor microenvironments (TME; ref. 2). In particular, as tumors progress, cancer cells produce signals that educate TAMs to secrete a variety of cytokines, growth factors, inflammatory substrates, and proteolytic enzymes involved in cancer progression, malignancy, and resistance to standard-of-care therapeutic interventions (2, 3). Accordingly, TAM abundance has been associated with worse patient prognosis in many, if not all, solid tumors (4, 5). Hence, there has been significant interest in devising macrophage-centered approaches for cancer treatment (2, 3, 6, 7). However, the potential of efficient tailored TAM-directed therapies will only be revealed once the full spectrum of molecular mechanisms governing the programming of protumoral macrophages is discovered.

As a representative example, we have recently analyzed the phenotypic consequences of selective ablation of the ERK5 in the myeloid lineage (8). ERK5 belongs to the family of MAPKs that play key roles in transducing extracellular cues into a wide variety of cellular responses, including changes in gene expression (9). Like other MAPKs, ERK5 is activated upon stimulation by dual phosphorylation of the canonical MAPK activation motif Thr-Glu-Tyr by the MAPK/ERK kinase 5 (MEK5). Nonetheless, ERK5 is very different from the other members of the MAPK family due to a unique extended C-terminal tail (9). The importance of ERK5 in signal transduction is further supported by compelling genetic evidence that the pathway exerts nonredundant functions in vivo (10). Notably, we found that ERK5 was required for TAM education by cancer cells (8). Coincidentally, myeloid ERK5 deficiency impaired the growth of 4434 melanoma and Lewis lung adenocarcinoma (LL2) tumor grafts in mice (8). The tumor growth defect caused by the absence of ERK5 correlated with reduced TAM density, in addition to abnormal macrophage polarization (8).

There is compelling evidence that TAM accumulation is a consequence of the constant recruitment of circulating mononuclear precursors in the blood, originating from hematopoietic stem cells (HSC) in the bone marrow (11–13). However, other studies revealed that TAMs could also originate from tissue resident macrophages derived from the embryonic yolk sac (14, 15). Furthermore, macrophages in tumor...
retain the capacity to proliferate (13, 16–19). This unique feature was shown to markedly contribute to increasing the pool of protumoral TAMs, whether they derive from the yolk sac or the bone marrow, in mammary (13) and pancreatic (20) tumors. Colony-stimulating factor 1 (CSF1, also known as M-CSF) is one of the main factors produced by tumor cells to control the number of TAMs in the TME through stimulation of the CSF1 receptor (21). A previous study showed that CSF1 exerted its mitogenic effect upon binding to the CSF1 receptor and the stimulation of ERK5 in macrophages (22). On the basis of these data, we sought to investigate the impact of ERK5 on TAM proliferation as an important mechanism by which tumor-educated macrophages exhibiting protumoral phenotypes and functions accumulate in the TME.

Materials and Methods

Animal welfare and human samples

Mice were maintained in a pathogen-free facility at the University of Manchester. All animal procedures were performed under license in accordance with the UK Home Office Animals (Scientific Procedures) Act (1986) and approved by the Animal Welfare and Ethical Review Body of the University of Manchester. In particular, mice with tumors were closely monitored by careful clinical examination to allow detection of deterioration of their physical condition. Animals showing signs of distress were sacrificed before any further deterioration in condition occurred. Formalin-fixed paraffin-embedded (FFPE) human tissues obtained with appropriate consents were retrieved from the tissue bank of the Department of Pathology (ASST Spedali Civili di Brescia, Brescia, Italy).

IHC analyses of human tissues

Four-micron-thick sections were double immunostained with antibodies to Ki67 (undiluted; clone 30-9 from Roche) and to CD163 (1:50 dilution; clone 10D6 from Thermo Fisher Scientific). Ki67 was revealed using Novolink Polymer (Leica Biosystems) followed by DAB. After completing the first immune reaction, antibodies to CD163 (1:50 dilution; clone 10D6 from Thermo Fisher Scientific), CD3 (dilution 1:80, clone LN10 from Leica Biosystems), CD20 (dilution 1:250, clone L26 from Leica Biosystems), CD117 (dilution 1:100, polyclonal from Agilent) or CD66b (dilution 1:150, clone G10F5 from Novus Biologicals) were visualized using MACH 4 MR-AP (Biocare Medical) and subsequently harvested, counterstained with hematoxylin. Sequentially double immunostaining was performed using a nonpermanent chromogen (Biocare Medical), CD117 (dilution 1:100, polyclonal from Agilent) or CD66b (dilution 1:150, clone G10F5 from Novus Biologicals) were visualized using MACH 4 MR-AP (Biocare Medical) and subsequently counterstained with hematoxylin. Sequentially double immunostaining was performed using a nonpermanent chromogen (AEC) to reveal Ki67. The slides were counterstained with hematoxylin. Sequentially double immunostaining was performed using a nonpermanent chromogen (AEC) to reveal Ki67. The slides were counterstained with hematoxylin. After digitization using Aperio Scanscope CS (Leica Biosystems), slides were decolorized and the Ki67 antibody was processed using synchronizing tool of ImageScope. Snapshots of 400× where taken from the two scans and corresponding tissue regions were analyzed using the counter tool. Overlapping of the single images where obtained using Adobe Photoshop.

Mice

Mice were identified by PCR on genomic DNA, as described previously (8). For melanoma grafts, 4434 melanoma cells were subcutaneously transplanted in the flanks of 8 to 12 weeks old syngeneic C57Bl/6 mice (8). For lung experimental metastasis, 2 × 10^5 B16F10 melanoma cells resuspended in 0.1 mL PBS were injected via the lateral tail vein using a 27-gauge needle. Mice were killed between 15 and 20 days after injection and tissues were isolated and fixed in 10% neutral-buffered formalin, prior to being processed for immunofluorescence analysis as described previously (8). Sections were counterstained with hematoxylin and eosin (H&E) and surface metastatic foci in lung left lobes were counted under a dissecting microscope. For quantitation of metastatic nodule size, photos of random fields were obtained (using low-magnification 4× and 10× lens), and then the sizes of at least 20 nodules were determined using NIH Image software (version 1.44) and averaged.

Flow cytometry

Mononuclear single-cell suspensions from mouse tumors, lungs, and spleen were obtained as indicated in the Supplementary Data available with this article online (Supplementary Materials and Methods) and analyzed by FACSC, as described previously (8). Antibodies utilized for flow cytometry analysis and magnetic bead purification are provided in the Supplementary Materials and Methods. For determining cell proliferation, primary bone-derived macrophages were pulse labeled in vitro with 100 μmol/L 5-bromo-2'-deoxyuridine (BrdUrd; Sigma) for 30 minutes at 37°C. Cells were subsequently harvested, fixed in 4% formaldehyde for 15 minutes at room temperature, and permeabilized by incubation in ice-cold methanol for 30 minutes. Cells were washed in PBS and incubated with a primary antibody to BrdUrd (1:200 dilution; CST#5292) for 60 minutes, followed by incubation with a secondary Alexa Fluor 488-conjugated anti-mouse IgG F(ab')2 fragment (1:100 dilution; CST#4408) for 30 minutes at room temperature.

Immunoblot analysis of bone marrow–derived macrophages

Primary murine macrophages were obtained from bone marrow cells isolated from femurs of wild-type (WT) or genetically modified mice and polarized by exposure to tumor cell-conditioned media (1/2 dilution), as described previously (8). erk5<sup>−/−</sup> and CMV-Cre<sup>ER</sup> erk5<sup>−/−</sup> macrophages incubated with 4-hydroxytamoxifen (4-HT, 0.1 μmol/L) were referred to as erk5<sup>−/−</sup> and erk5<sup>N/A</sup>, respectively. Proteins (30 μg) were subsequently extracted in RIPA buffer, resolved by SDS-PAGE and transferred to an Immobilon-P membrane (Millipore, Inc.). The membranes were saturated in 3% nonfat dry milk and probed overnight at 4°C with antibodies to ERK5 (1:1,000 dilution; CST3372), p21 (1:1,000 dilution; CST2947), or tubulin (1:1,000 dilution; CST2125). Immuno-complexes were detected by enhanced chemiluminescence with immunoglobulin G coupled to horseradish peroxidase as the secondary antibody (GE Healthcare).

Quantitative real-time PCR

Total RNA was reversed transcribed and quantified by RT-PCR using the SYBR Green I Core Kit (Eurogentec), as described...
previously (8). Sequences of the forward and reverse primers are indicated in the Supplementary Data available with this article online (Supplementary Table S1). Results were analyzed using the \(2^{-\Delta\Delta C_T}\) method. The level of expression of mRNA was normalized to Gapdh and Pgk1 mRNA.

**Statistical analysis**

All \(P\) values were generated using an unpaired Student \(t\) test and one-way ANOVA with Tukey’s correction for multiple comparisons. Data were analyzed using Prism software (GraphPad). For all tissue experiments, images are representative of cohorts of at least 3 mice.

**Data availability**

The authors declare that all data supporting the findings of this study are available within the article and its supplementary information files or from the corresponding authors on reasonable request.

**Results**

**Human neoplastic tissues comprise high numbers of proliferative macrophages**

To demonstrate that proliferating TAMs were characteristic of human cancer, we initially screened a large set of human primary malignant lesions \((n = 197)\) using tissue microarrays. Representative images show the noticeable increase in the number of proliferating macrophages \((\text{Ki67}^+\text{CD163}^+\text{cells})\) in squamous cell carcinoma (SCC), lung adenocarcinoma, and breast carcinoma compared with normal tissues (Fig. 1A–I). This was confirmed by quantitative analysis of Ki67 TAMS (Fig. 1J–L). The number of Ki67^+CD163^+, as well as the total number of macrophages, are included in Supplementary Table S2A. Likewise, a high number of proliferating TAMs was detected in primary human hepatocarcinoma, colon, ovary, bladder carcinoma, melanoma, mesothelioma, and metastatic melanoma and carcinoma (Supplementary Fig. S1). To explore the possibility that macrophage accumulation through proliferation was a significant feature of malignancy, we compared...
Giurisato et al.

Figure 2.

Proliferating TAMs in primary and metastatic melanomas. Sections from benign nevus (A and B), PCM (C-F) at different pathologic stages, and dermal metastasis of cutaneous melanoma (MM; G and H) were double stained for Ki67 (brown) and CD163 (blue). Original magnification, ×100; scale bar, 200 μm (A, C, E, and G) and ×400; scale bar, 50 μm (B, D, F, and H). I, The clinical significance of TAM proliferation in melanocytic lesions was tested by counting the number of double-positive cells (Ki67\(^+\) CD163\(^+\)) in benign nevi (n = 10), PCM (n = 20), and MM (n = 10). The data presented as percentages of proliferating macrophages in the four pathologic groups correspond to the mean ± SD. \(* P < 0.05; \** P < 0.01; \*** P < 0.001\) compares between distinct pathologic stages.

We observed that the percentage of proliferating TAMs significantly increased as the disease progressed (Fig. 2I; Supplementary Table S2A). In contrast, no marked difference was observed between benign nevus and normal skin tissues. Together, these observations clearly indicated that local macrophage proliferation was a common hallmark of human tumors and a potentially important prognostic marker of malignancy.

Tumor macrophage proliferation is dependent on ERK5

We had previously found that macrophage density was markedly reduced in carcinoma grafts derived from myeloid ERK5 deficient mice compared with controls (8). Utilizing a similar approach based on our LysM-Cre\(erk5^{f/f}\) model, we confirmed that the number of TAMs in melanoma grafts decreased by almost two-fold in the absence of ERK5 (Supplementary Figs. S2A and S2B). Accordingly, the percentage of Gr1\(^+\) F4/80\(^+\) macrophages expressing CD206 was reduced in melanoma grafts derived from LysM-Cre\(erk5^{f/f}\) mice compared with that from erk5\(^{f/f}\) (Supplementary Figs. S2C–S2E). Importantly, the reduction in macrophage density caused by myeloid ERK5 deficiency coincided with reduced melanoma cell proliferation in the tumor (Supplementary Fig. S3).

On the basis of these data, we examined a possible association between ERK5 expression and tumor macrophage proliferation in human cancer. This was achieved by employing Aperio Scanscope digitalization to sequentially detect Ki67 (AEC) and ERK5 (brown) in CD163\(^+\) (blue) cells in human tumor sections. Between 60% and 50% of proliferating TAMs in lung metastasis of cutaneous melanoma and ovarian carcinoma expressed ERK5 in the nucleus (Fig. 3A–F). Likewise, nuclear ERK5 was detected in around 90% and 40% of Ki67\(^+\) CD163\(^+\) macrophages present in cell blocks of pleural effusion of lung adenocarcinoma (Fig. 3G–I) and cytospin preparation of peritoneal wash of ovarian carcinoma (Fig. 3J–L), respectively. Proliferating ERK5\(^+\) macrophages were found in both intratumoral area (cutaneous melanoma) and intratumoral stroma (second raw ovarian carcinoma). Further analyses of breast carcinoma also demonstrated the presence of Ki67\(^+\) ERK5\(^+\) macrophages in peritumoral area, close to tumor vessel at the invasion edge (Supplementary Fig. S4). On the basis of these observations, we concluded that human tumors comprised a high proportion of proliferating TAMs expressing ERK5 scattered around the tissue. Unlike TAMs, CD11\(^{+}\) mast cells and CD56\(^+\) neutrophils exhibited a predominantly cytoplasmic ERK5 staining, indicative of a low level of ERK5 activity in these cells (Supplementary Fig. S5). Moreover, the number of ERK5-expressing CD3\(^{+}\) T and CD20\(^{+}\) B cells was very low, suggesting that ERK5 might not play a critical role in the adaptive immune system of the TME (Supplementary Fig. S5).

To establish whether ERK5 was required for mediating tumor macrophage proliferation, we sought to analyze the impact of myeloid ERK5 deficiency in excised murine melanoma and carcinoma grafts. Tumor sections were processed by immunofluorescence staining with antibodies to Ki67 and to Iba1, a commonly used cell surface marker to label total TAMs. The results showed around 50% reduction in the proportion of proliferating Ki67\(^+\)Iba1\(^+\) macrophages in tumors derived from LysM-Cre\(erk5^{f/f}\) mice compared with erk5\(^{f/f}\) controls (Fig. 4A and B; Supplementary Figs. S6A and S6B; Supplementary Table S2B). Moreover, ERK5-deficient macrophages purified from melanoma or carcinoma grafts expressed a lower level of positive regulators of cell proliferation, for example, Ets2, Ki67, and c-Jun transcripts, compared with WT cells (Fig. 4C; Supplementary Fig. S6C). Conversely, carcinoma macrophages lacking ERK5 exhibited increased mRNA expression of two important transcription factors.
factors associated with macrophage differentiation, namely c-Maf and MafB (Supplementary Fig. S6C). A similar increase in c-Maf level was detected in purified ERK5-deficient macrophages from melanoma, although no significant difference was observed in MafB expression (Fig. 4C). In addition, the cyclin-dependent protein kinase inhibitor p21 was significantly upregulated in the absence of ERK5 (Fig. 4C; Supplementary Fig. S6C). We confirmed by immunoblot analysis that p21 protein level was noticeably increased in LysM-Creerk5F/F macrophages polarized in vitro by incubation with melanoma 4434 cell-conditioned medium (Supplementary Fig. S7A). This coincided with increased p53 expression and decreased level of pSTAT3(Tyr705) and cyclin D1. In contrast, the absence of ERK5 did not affect ERK1/2 (Supplementary Fig. S7A).

**ERK5 is a key suppressor of p21 expression during the maturation and differentiation of monocytes into macrophages**

To provide direct evidence that ERK5 was a positive regulator of TAM proliferation, we prepared genetically modified macrophages...
Figure 4. Myeloid ERK5 is required for TAM proliferation. A, Immunofluorescence imaging of melanoma graft sections stained for Iba1 (red) and Ki67 (green). DNA was stained with DAPI (blue). Scale bar, 15 μm. B and C, Quantification (B) of proliferating (Ki67+) macrophages (Iba1+) in tumor grafts with ImageJ and qRT-PCR analysis (C) of positive (Ets2, Ki-67, c-Jun) and negative (c-Maf, MafB and p21) cell-cycle regulators in Gr1+/F4/80+ sorted macrophages from 4434 melanoma tumor grafts derived from erk5F/F and LysM-Cre;erk5F/F mice. The data correspond to the mean ± SD (n = 3 tumors per genotype). *, P < 0.05 compares tumor grafts from erk5F/F and LysM-Cre;erk5F/F mice. ns, no significant difference. D and E, Histograms represent quantitative analysis of BrdUrd+ macrophages (D) and qRT-PCR analysis of Ki-67 and p21 expression in NP and 4434 polarized erk5wt and erk5−/− macrophages (E). The data correspond to the mean ± SD of three independent experiments performed in triplicate. *, P < 0.05 compares erk5wt and erk5−/− macrophages. F, Immunoblot analysis of ERK5 and p21 expression in erk5wt and erk5−/− macrophages cultured for 9 days in vitro prior to being exposed to 4434-CM for 48 hours. Tubulin expression was used as loading control.
from the bone marrow of CMV-Cre<sup>ER</sup>erk5<sup>F/F</sup> mice to permit inducible erk5 deletion in vitro by incubation with 4-HT (Supplementary Fig. S7B). Initially, we confirmed by short-term BrdUrd incorporation that nonpolarized (NP) macrophages in steady state were mostly quiescent, whereas more than 20% of macrophages polarized by incubation with 4434 melanoma cell-conditioned media (4434-CM) were actively replicating their DNA (Fig. 4D). Increased tumor macrophage proliferation was clearly reduced in the absence of ERK5 (Fig. 4D). Accordingly, polarized erk5<sup>野生型</sup> macrophages exhibited a much lower level of Ki67 transcript compared with WT cells (Fig. 4E). This correlated with a significant upregulation of p21 at mRNA and protein level (Fig. 4E and F). These results led us to conclude that ERK5 was required for mediating the mitogenic response of macrophages to tumor soluble factors, at least in part, via suppressing p21 expression.

We and others had previously observed that functional disruption of ERK5 signaling advanced macrophage differentiation in vitro (8, 23). Therefore, we tested whether the mitogenic effect of ERK5 was a consequence of its ability to suppress differentiation. Consistent with our previous data, ERK5 ablation in bone marrow cells impaired the ability of maturing macrophages to proliferate (Fig. 5A; Supplementary Figs. S7C and S7D). Moreover, the absence of ERK5 significantly accelerated the kinetic of monocytic differentiation in vitro (Fig. 5B and C). Notably, the intensity of F4/80 and CD115 staining was distintively higher in erk5<sup>F/F</sup> compared with erk5<sup>野生型</sup> maturing macrophages at day 3, indicative of a more advanced macrophage differentiation in the absence of ERK5 (Fig. 5C and D). Interestingly, the differentiation of erk5<sup>F/F</sup> monocytes was associated with a strong upregulation of p21 expression (Fig. 5E). Given that p21 is crucial for the maturation and differentiation of macrophages (24, 25), we proposed that the downregulation of p21 expression by ERK5 constituted one potentially important mechanism that maintains macrophages in a phenotypic state capable of responding to mitogenic factors produced by cancer cells (Fig. 5F).

**Inhibition of ERK5 activity blocks tumor macrophage proliferation**

The detection of an electrophoretic migratory shift characteristic of ERK5 phosphorylation provided evidence that ERK5 was activated in macrophages stimulated with 4434-CM or B16F10-CM (Supplementary Fig. S8A). Accordingly, preincubation with the JWG-045 compound caused the disappearance of the slow migrating band as a consequence of inhibition of ERK5 activity and the loss of C terminal tail autophosphorylation (Supplementary Fig. S8A). In contrast, JWG-045 did not affect ERK1/2 phosphorylation. Similar to the loss of ERK5 protein expression, inhibition of ERK5 by JWG-045 reduced by half the number of proliferating tumor macrophages (Supplementary Figs. S8B and S8C). However, given that the first generation of pharmacologic ERK5 inhibitors exhibited nonspecific effect on BRD4 proteins (26), we wanted to insure that ERK5 activation was essential for promoting the proliferation of TAMs by other means. Therefore, erk5<sup>F/F</sup> macrophages were coinfected with adenoviruses encoding Ha-tagged constitutive active (ca) MEK5 and flag-tagged (F) WT or dominant negative mutant (AEF) ERK5 (Supplementary Fig. S9A). As expected, ERK5(AEF) did not display the mobility retardation shift characteristic of ERK5(WT) phosphorylation by caMEK5 (Supplementary Fig. S9B). Moreover, unlike ERK5(WT), ERK5(AEF) expressed together with caMEK5 significantly reduced the number of proliferating macrophages exposed to 4434-CM (Supplementary Figs. S9C and S9D). Collectively, these data demonstrated that ERK5 activation by MEK5 was critical for tumor-induced macrophage proliferation.

**ERK5-mediated macrophage proliferation supports melanoma tumor metastasis in vivo**

Given the correlation between TAM proliferation and melanoma invasiveness in human (Fig. 2), we sought to investigate the impact of myeloid ERK5 deficiency in metastasis. Melanoma B16F10 cells were transplanted intravenously via the tail vein in erk5<sup>F/F</sup> and LysM-Cre;erk5<sup>F/F</sup> mice. Animals were sacrificed after 2 to 3 weeks and postmortem analyses showed that the lungs of LysM-Cre;erk5<sup>F/F</sup> mice exhibited less metastases compared with control erk5<sup>F/F</sup> animals (Fig. 6A). Quantitative analysis indicated that the number of metastatic lung nodules was reduced by half in myeloid ERK5-deficient mice (Fig. 6B). To further characterize the metastasis lowering associated with myeloid ERK5 ablation, lung sections of erk5<sup>F/F</sup> and LysM-Cre;erk5<sup>F/F</sup> transplanted mice were processed by H&E staining. Metastatic foci in both groups were distributed as perivascular and subpleural lesions (Fig. 6C). However, consistent with our previous macroscopic observation, their number and size were significantly lower in the absence of ERK5 (Fig. 6C and D). Immunofluorescence analysis of lung tissue sections with an antibody to Iba1 confirmed that ERK5 ablation significantly reduced TAM density in melanoma metastases (Supplementary Fig. S10). Accordingly, lungs of B16F10-bearing LysM-Cre;erk5<sup>F/F</sup> animals exhibited a much lower percentage of Gr1<sup>+</sup>F4/80<sup>+</sup> macrophages (Fig. 6E and F). We also noted that, although there was no difference in the number of Gr1<sup>+</sup>F4/80<sup>+</sup> neutrophils, the percentage of Gr1<sup>+</sup>F4/80<sup>+</sup> monocytes was significantly lower in LysM-Cre;erk5<sup>F/F</sup> than in erk5<sup>F/F</sup> lung samples (Fig. 6F). This coincided with a lower number of circulating LysM-Cre;erk5<sup>F/F</sup> CD11b<sup>+</sup>F4/80<sup>+</sup> monocytes (Supplementary Fig. S11A). Accordingly, myeloid ERK5 deficiency significantly reduced the percentage of monocytes proliferating in the blood or in the bone marrow of B16F10 transplanted animals (Supplementary Figs. S11B and S11C).

Lung macrophages from erk5<sup>F/F</sup> and LysM-Cre;erk5<sup>F/F</sup> naïve and B16F10-bearing mice were subsequently analyzed by flow cytometry to distinguish interstitial (infiltrating) from alveolar (resident) macrophages based on different level of expression of CD11b and Cd11c markers (27, 28). CD64 was utilized as an alternate marker to F4/80 to distinguish macrophages from dendritic cells. As expected, normal lungs were devoided of CD11b<sup>+</sup>CD64<sup>+</sup> interstitial macrophages (Supplementary Figs. S12A and S12B). Moreover, the small percentage of CD11c<sup>+</sup>CD64<sup>+</sup> alveolar macrophages was unaffected by the absence of ERK5 (Supplementary Figs. S12C and S12D). In contrast, the absence of ERK5 reduced the percentage of both interstitial (CD11c<sup>+</sup>/F4/80<sup>+</sup>) and alveolar (CD11c<sup>+</sup>/F4/80<sup>+</sup>) macrophages in metastatic lung nodules (Fig. 7A and B). F4/80<sup>+</sup> cells were subsequently purified by magnetic-assisted cell sorting, and CD11b<sup>+</sup> and CD11c<sup>+</sup> macrophages were analyzed separately by flow cytometry for Ki67 expression (Supplementary Fig. S13A). We confirmed that F4/80<sup>+</sup> sorted cells were positive for CD64 expression (Supplementary Figs. S13B and S13C). Importantly, we found that myeloid ERK5 deficiency decreased the number of proliferating metastatic lung interstitial (Fig. 7C and D) and alveolar (Fig. 7E and F) macrophages. Together, these findings provided a further compelling demonstration that ERK5-mediated macrophage proliferation was an integral component of tumor malignancy.

**Discussion**

Targeted therapies aimed at depleting macrophages in the TME have been actively pursued to combat various cancers (2, 3, 6, 7). One of the most advance approaches rely on the blockade of CSF1/CSF1 receptor, given that CSF1 is highly expressed in several types of human...
Figure 5. ERK5 suppresses macrophage differentiation through negative regulation of p21. A, Flow cytometry analysis of BrdUrd incorporation in macrophages derived from the maturation of erk5<sup>wt</sup> and erk5<sup>Δ/Δ</sup> monocytes. The percentage of BrdUrd<sup>+</sup> cells is indicated in the plot. B–D, Flow cytometry analysis and quantification of F4/80<sup>+</sup>CD86<sup>+</sup> (B and C) and F4/80<sup>+</sup>CD115<sup>+</sup> (D) cells during the maturation (days 0, 3, and 5) of erk5<sup>wt</sup> and erk5<sup>Δ/Δ</sup> monocytes/macrophages. The level of expression of F4/80 and CD115 (MFI) is indicated in each histogram plot. Data are representative of at least two independent experiments. E, Immunoblot analyses show that ablation of ERK5 in monocytes/macrophages correlates with increased p21 expression. Tubulin expression was used as loading control. Similar results were obtained in two independent experiments. F, Schematic model illustrating how ERK5 blocks macrophage differentiation by suppressing p21 expression.
tumors with poor patient outcomes and the dominant role of this signaling pathway in fostering the development of various populations of macrophages exhibiting protumor properties (29, 30). In particular, in mammary cancer, CSF1 produced by tumor cells was shown to drive the accumulation of TAMs that supply the neoplasm with the crucial EGF (31). This was consistent with an earlier study, which demonstrated that the genetic loss of \textit{csf1} significantly reduced metastasis in mammary tumors (32). Importantly, although less effective, neutralizing CSF1 in breast cancer xenografts decreased tumor growth (33). Further studies confirmed that depleting TAMs by CSF1R signaling blockade delayed tumor progression and reduced metastasis, but also enhanced the efficacy of several other standard therapies in various murine models of solid tumors (30).

However, despite these promising results, clinical trials have brought modest clinical benefits for patients with cancer, emphasizing the necessity for far more in depth understanding of the mechanisms underpinning the accumulation of protumoral macrophage populations in preclinical settings. In particular, despite being differentiated, macrophages preserve a certain capacity to self-renew in response to various environmental cues (34). This is significant given that subsets

Figure 6. Myeloid ERK5 supports melanoma tumor metastasis in vivo. A, Representative pictures of lungs bearing metastases 18 days after intravenous transplantation of B16F10 melanoma cells in the tail vein of \textit{erk5FF} and LysM-Cre;\textit{erk5FF} mice. B, Quantification of the number of metastatic lung nodules in mice. * \( P < 0.01 \) indicates a significant difference between \textit{erk5FF} and LysM-Cre;\textit{erk5FF} (\( n = 10 \) animals per genotype). C, Representative H&E sections of lungs from \textit{erk5FF} and LysM-Cre;\textit{erk5FF} mice, 18 days after transplantation of melanoma cells. Arrows, metastatic foci. Scale bar, 200 \( \mu \)m. D, Size distributions of B16F10 metastatic foci. * \( P < 0.01 \) indicates a significant difference between \textit{erk5FF} and LysM-Cre;\textit{erk5FF} (\( n = 14 \) animals per genotype). E, Representative flow cytometry analysis and quantification of live (DAPI) myeloid cell populations in the lung, 18 days after transplantation of melanoma cells. F, Graphical analysis of \( E \) showing a specific reduction in the percentage of Gr1 \( ^{+} \) F4/80 \( ^{+} \) macrophages in lungs from LysM-Cre;\textit{erk5FF} animals bearing melanoma metastases. The data correspond to the mean \( \pm SD \) (\( n = 3 \) animals per genotype). * \( P < 0.05 \) compares \textit{erk5FF} and LysM-Cre;\textit{erk5FF} mice. ns, no significant difference.
of TAMs were observed to proliferate in sarcomas (17), breast carcinomas (13, 18, 19), and pancreatic cancer (20). Furthermore, there is a possibility that increased macrophage proliferation following the cessation of TAM depletion contributes to accelerating tumor growth in a murine model of breast cancer metastasis (35). Our demonstration that macrophage proliferation was a common feature of cancer patients across various malignant tumor types added further weight to the idea that pools of macrophages can expand through local self-renewal in tumor tissue. Consistent with evidence that TAM density positively correlates with the malignant progression of most solid tumors (2–5), including melanoma (36, 37), decreased TAM proliferation caused by myeloid ERK5 ablation halted the growth of murine melanoma graft (8) and the capacity of melanoma cells to form lung metastasis.

On the basis of previous analyses of ERK5 in cancer cells, ERK5 activity may promote macrophage proliferation by suppressing p53-

Figure 7.
ERK5 deficiency blocks alveolar and interstitial macrophage proliferation in melanoma lung metastasis. A, Representative flow diagram and quantification of CD11c<sup>+</sup>/F4/80<sup>+</sup> (alveolar) and CD11clow/F4/80<sup>+</sup> (interstitial) macrophages in the lung of mice 18 days after transplantation of B16F10 melanoma cells. B, Graphical analysis of A showing a reduced percentage of alveolar and interstitial macrophages in the lungs of LysM-Cre;erk5<sup>F/F</sup> mice. The data correspond to the mean ± SD (n = 3 tumors). C–F, F4/80<sup>+</sup> sorted macrophages from A were separately analyzed for the expression of CD11b, CD11c, and Ki67. Representative plots and quantification of proliferating F4/80<sup>+</sup> interstitial (CD11b<sup>+</sup>/Ki67<sup>+</sup>; C and D) and alveolar (CD11c<sup>+</sup>/Ki67<sup>+</sup>; E and F) macrophages are shown. The data correspond to the mean ± SD (n = 3 tumors). *P < 0.05 compares erk5<sup>F/F</sup> and LysM-Cre;erk5<sup>F/F</sup> mice.
mediated transcriptional upregulation of p21 through blocking PML-dependent sequestration of MDM2 in cancer cells (38, 39). Further experiments will need to be conducted to provide a definite molecular link between p53 and p21 in ERK5-deficient macrophages, given that p21 can be induced via both p53-dependent and -independent mechanisms (40). For example, we have previously proposed that ERK5 blocked p21 upregulation through c-Myc-dependent transcriptional regulation of miR-17-5p and miR-20a in breast cancer cells (41). Moreover, in light of previous evidence that p21 was crucial for the maturation and differentiation of macrophages (24, 25), we anticipate that ERK5 supports macrophage proliferation through blocking differentiation, rather than having a direct effect on the cell cycle. This model is consistent with our demonstration that ERK5-deficient monocytes/macrophages exhibiting a high level of p21 differentiated more rapidly. The requirement of ERK5 to regulate the level of p21 might also be responsible for causing increased STAT3 signaling and the acquisition of protumorigenic TAM phenotypes (8, 42).

Mechanistically, the ability of ERK5 to block macrophage differentiation might involve decreased expression of transcription factors of the Maf family, given that cMaf/MafB deficiency rendered functionally differentiated macrophages capable of expanding through self-renewal via KLF4 and c-Myc (43). Consistently, a further analysis demonstrated that transient downregulation of Maf transcription factors was required for proliferating resident macrophages (44). Moreover, both KLF4 and c-Myc, which have been implicated in pluripotent stem cell reprogramming (45), are ERK5 targets (46, 47). However, a recent study showed that cMaf was a transcriptional regulator of protumoral macrophage activation (48). In the future, unbiased transcriptomic studies to establish the transcriptional network downstream of ERK5 will be essential to understand how ERK5 maintains proliferative protumor macrophage populations to support tumor progression and malignancy. In particular, these data will clarify the requirement of Maf factors downstream of ERK5 and may reveal potential important functional cross talks between p21, Maf, and STAT3 implicated in protumoral macrophage polarization.

In summary, we demonstrate in this study that TAM proliferation is a general mechanism in cancer. Moreover, we provide a novel insight into TAM self-renewal with the potential clinical implication of pharmacologic inhibition of ERK5, alone or combined with other therapeutic strategies based on blocking the survival or the recruitment of macrophages (49), to achieve long-term control of malignancy and endure remission for patients with cancer.

Disclosure of Potential Conflicts of Interest

N. Gray reports personal fees from Syros, Petra, C4 Therapeutics, Aduro, B2S, Gatekeeper, Soltego, Jengu, and Allorion, as well as grants from Deerfield, Taico, and Takeda outside the submitted work; and Nathanael Gray is a founder, science advisory board member (SAB), and equity holder in Gatekeeper, Syros, Petra, C4, B2S, Aduro, Allorion, Jengu, and Soltego (board member). The Gray lab receives or has received research funding from Novartis, Takeda, Astellas, Taico, Janssen, Kinogen, Voronoi, Arberla, Deerfield, and Sanofi. No potential conflicts of interest were disclosed by the other authors.

Authors’ Contributions


Acknowledgments

This work was supported by grants mainly from Worldwide Cancer Research to Cathy Tournier and partly from the Medical Research Council Confidence in Concept (GC7) scheme to K. Finegan, and by a Marie Curie Research Fellowship to E. Giurisato. S. Lussosso was supported by Fondazione Beretta and W. Vermi was supported by Associazione Italiana per la Ricerca sul Cancro (IG grant no. 15378). We are grateful to Sara Licini and Debra Brenci (supported by Fondazione Beretta) for their excellent support on preparation of human tissue biopsies and image processing. We thank Michael Cross for providing adenosviruses particles expressing c-MEKS and ERK5. We thank Peter March and Peter Walker (Bioimaging and Histology Facilities, University of Manchester) for very helpful advice and the staff at the University of Manchester Biological Safety Unit for looking after the mice.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received August 5, 2019; revised April 7, 2020; accepted June 12, 2020, published first June 19, 2020.

References


Targeting ERK5 Blocks TAM Proliferation and Tumor Malignancy

Cancer Res; 80(16) August 15, 2020 3329
Giurisato et al.


Extracellular-Regulated Protein Kinase 5-Mediated Control of p21 Expression Promotes Macrophage Proliferation Associated with Tumor Growth and Metastasis

Emanuele Giurisato, Silvia Lonardi, Brian Telfer, et al.


Updated version
Access the most recent version of this article at:
doi:10.1158/0008-5472.CAN-19-2416

Supplementary Material
Access the most recent supplemental material at:
http://cancerres.aacrjournals.org/content/suppl/2020/06/19/0008-5472.CAN-19-2416.DC1

Cited articles
This article cites 49 articles, 19 of which you can access for free at:
http://cancerres.aacrjournals.org/content/80/16/3319.full#ref-list-1

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, use this link http://cancerres.aacrjournals.org/content/80/16/3319.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.